{"organizations": [], "uuid": "2a3d8f4674733a223d4ce46a077ebafdf2b9cd89", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180329.html", "section_title": "Archive News &amp; Video for Thursday, 29 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-redx-pharma-says-temporarily-inter/brief-redx-pharma-says-temporarily-interrupting-patient-accrual-to-phase-1-2a-clinical-study-for-porcupine-inhibitor-idUSASO0002S4", "country": "US", "domain_rank": 408, "title": "Redx Pharma says temporarily interrupting patient accrual to phase 1/2a clinical study for porcupine inhibitor​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.969, "site_type": "news", "published": "2018-03-29T14:57:00.000+03:00", "replies_count": 0, "uuid": "2a3d8f4674733a223d4ce46a077ebafdf2b9cd89"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-redx-pharma-says-temporarily-inter/brief-redx-pharma-says-temporarily-interrupting-patient-accrual-to-phase-1-2a-clinical-study-for-porcupine-inhibitor-idUSASO0002S4", "ord_in_thread": 0, "title": "Redx Pharma says temporarily interrupting patient accrual to phase 1/2a clinical study for porcupine inhibitor​", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "redx pharma", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "redx pharma plc", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 29 (Reuters) - Redx Pharma Plc:\n* RXC004 CLINICAL TRIAL UPDATE * ‍TEMPORARILY INTERRUPTING PATIENT ACCRUAL TO ITS PHASE 1/2A CLINICAL STUDY FOR PORCUPINE INHIBITOR, RXC004​\n* CURRENT INTENTION TO PROPOSE PROTOCOL AMENDMENT THAT ENABLES DOSE- ESCALATION TO RE-START AT SIGNIFICANTLY LOWER DOSE LEVELS​ Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T14:57:00.000+03:00", "crawled": "2018-03-30T13:24:04.008+03:00", "highlightTitle": ""}